4 results about "Cefdinir" patented technology

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 2). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: the front view. 5. The design for which protection is sought includes color.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 3). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The design for which protection is sought includes color.

The invention belongs to the field of medicinal chemistry, and discloses an application of a ferrous ion complex of dihydrochalcone compounds (phlorizin, PHL) and trilobatin, TLB) in prevention and treatment of food-borne microorganisms, and a preparation method of the ferrous ion complex of the dihydrochalcone compounds (phlorizin, PHL) and the trilobatin, TLB). The phlorizin-ferrous ion complex and the trilobatin-ferrous ion complex have relatively good DPPH (1, 1-diphenyl-2-picrylhydrazyl) scavenging capacity and hydroxyl radical scavenging capacity; the phlorizin-ferrous ion complex and the trilobatin-ferrous ion complex can slow down oxidation of edible oil and fat; the phlorizin-ferrous ion complex and the trilobatin-ferrous ion complex have different inhibitory activities on the tested food-borne microorganisms; when the compound is combined with the cefdinir for use, the phlorizin-ferrous ion and trilobatin-ferrous ion complexes can synergistically promote the antibacterial effect of the cefdinir, and the use dosage of the cefdinir is reduced. The two have the potential of being further researched and developed into a novel edible antibacterial agent.